fda glp-1 compounding warning october 2025 is moving to restrict mass-marketed compounded products that aren't FDA-approved, companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Compounding GLP-1 Drugs - Recent

Interestingly, we reported the enrichment of Bifidobacterium only in T2 and T3, which although could be consistent with the phenotype observed in T3, it is somewhat incompatible with the reduced DMD, or AME observed in T2

"Clinicians know that most of their GLP-1 patients will eventually stop the medication, and without new habits the weight tends to come back," said Geoff Cook, CEO of Noom

Currently, there arent enough studies to determine whether semaglutide can directly cause UC flares

Approved GLP-1 medications undergo rigorous bioavailability testing to ensure therapeutic drug levels reach systemic circulation